Last reviewed · How we verify
NCT05362097
Analysis of the Reliability and Validity of the Chinese Version of CC-QoL
trial testing The reliability and validity of the Chinese version of CC-QoL in Chronic Cough in 180 participants. Currently enrolling.
30 December 2024
Quick facts
| Lead sponsor | Guangzhou Institute of Respiratory Disease |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 180 |
| Start date | 5 March 2023 |
| Primary completion | 30 December 2024 |
| Estimated completion | 5 May 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- The reliability and validity of the Chinese version of CC-QoL
Conditions studied
- Chronic Cough — all drugs for Chronic Cough →
Sponsor
Guangzhou Institute of Respiratory Disease
Who can join
Adults 7 to 14, any sex, with Chronic Cough. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
At present, there is no research scale designed for the quality of life of children with chronic cough in China, most of them use the cough scale designed for adults to evaluate the quality of life of children. In China, more and more attention has been paid to evaluate and improve the quality of life of children with chronic cough, but cough specific quality of life measurement tools for adults and parents are mostly used, and the Chinese translation version of CQLQ and LCQ is still the main method. There is still no cough specific quality of life measurement tool for children with chronic cough in China. Cc-qol, a specific scale for chronic cough in children, has not been promoted, and no relevant verification of the applicability, validity and reliability of the Chinese version has been found. Therefore, this study aims to verify and compare the applicability, reliability and validity of CC-QOL Chinese version in China through questionnaire survey and follow-up of children with chronic cough.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05362097
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Cough
Currently open trials in the same condition.
- NCT07488598 — Efficacy of Behavioral Therapy for Chronic Refractory Cough · NA · recruiting
- NCT06542484 — The Real-world Treatment Satisfaction by Gefapixiant in RCC · NA · recruiting
- NCT05813223 — Effect of Gefapixant on Cough-related Brain Activity in Patients With Chronic Cough · EARLY_PHASE1 · recruiting
- NCT06286163 — Neuroinflammatory Interactions of ATP and P2X3 Receptor in the Airways of Chronic Cough Patients · recruiting
- NCT06376448 — An Observational Study Using Novel Questionnaire to Characterize Cough Phenotypes in Patients With Chronic Cough · recruiting
Other Guangzhou Institute of Respiratory Disease trials
Trials by the same sponsor.
- NCT07092137 — Nano-crystalline Megestrol Acetate for Anorexia-Cachexia Syndrome in Advanced Lung Cancer · Phase 2 · not yet recruiting
- NCT06909383 — Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Can · Phase 2 · not yet recruiting
- NCT07005999 — Interventional Ablation for Early-stage Lung Cancer · active not recruiting
- NCT06739928 — Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC · Phase 2 · recruiting
- NCT06715956 — Observational Study of Sputum Inflammation Phenotypes and Clinical Outcomes in Non-Cystic Fibrosis Bronchiectasis · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05362097 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangzhou Institute of Respiratory Disease
- Last refreshed: 2 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05362097.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing